![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Declaration of interest
J Maher is chief scientific officer, shareholder and scientific founder of Leucid Bio, which is a spinout company focused on development of cellular therapeutic agents. D Larcombe-Young is a consultant to Leucid Bio. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.
Additional information
Funding
Work in the authors' lab is supported by Leucid Bio, Breast Cancer Now, British Lung Foundation, the Medical Research Fund, the Wellcome Trust, the JP Moulton Charitable Foundation, the Experimental Cancer Medicine Centre at King’s College London, the King’s Health Partners/King’s College London Cancer Research UK Cancer Centre and by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.